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Three Programs, One Goal: Equity
US Program
» High school education
» Public library internet access
Global Development
» Financial services for the poor (e.g. microfinance)
» Agricultural productivity and markets
Global Health
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Perspective on Global Health
The vision:
To ensure that a child born in the developing 
world has the same chance for good health as 
a child born in the developed world
The goal:
Build on advances in science and technology 
to save lives, improve health, and reduce 









HIV (vaccines, microbicides, treatment, prevention, education)
TB (drugs, vaccines, diagnostics)














Global Alliance for Vaccines and Immunization (GAVI)
Global Fund for AIDS, TB and Malaria
HIV Vaccine Enterprise
Medicines for Malaria Venture (MMV)
Malaria Vaccine Initiative (MVI)
MACEPA
PATH Vaccine Solutions (PVS)
Aeras (TB Vaccines)
Global Alliance for TB Drug Development (GATB)
ACHAP

















• IP or low price in 
LDCs
• Rapid access 
• Recognition as 
catalyst
Industry gets
• IP and pricing for rich 
countries
• Essential financing for 
small biotech firms
• New technology 














• LDC trial sites
• Access/distribution plans
• Market analysis




» To encourage scientific risk-taking on creative, unorthodox 
ideas for global health
THE INITIATIVE
» US$100 million funding initiative over 5 years
» Will fund hundreds of projects based on two-page submission – next 
round opens September 15th
» Initial grants of $100,000 with potential for additional funding (~$1M) if 
promising
» Opportunity for direct engagement with the private sector
» Sign up at www.gcgh.org/explorations/ for email updates
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Pre-clinical research 





To identify specific candidate antigens that 
generate protective immune responses 
against Trypanosoma brucei in cattle
To further test plant-based transient gene 
expression systems for production of 




Parasitic disease limited to tropical Africa
60M people at risk; affects all ages
~40-60K annual deaths – most die unreported in 
the bush (~300-500K?)
Resurgence of disease
Billions of $ of lost agricultural productivity
World’s greatest disparity disease
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Trypansome tubulin-rich regions as 
“Achilles Heel”
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Slide provided by Dr. Yusibov, Fraunhofer CMB
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Protection rate (%)Antigen used
0Negative control
33Btub (rec. full length)












Protection rate (%)Vaccine candidate
Experiment #1 Experiment #2
Slide provided by Dr. Yusibov, Fraunhofer CMB
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Days post challenge
Groups cow -4 7 10 12 14 17 40 45
AlMV 1 - - - + + + + +
2 - + + + + + + +
3 - + + + + + + +
4 - + + + + + + +
Btub2+ Btub5 1 - - - - - + + +
2 - - - - - + + +
3 - - - - - + + +
4 - - - - - + + +
Parasitemia in cattle post challenge 
with T. brucei brucei
Slide provided by Dr. Yusibov, Fraunhofer CMB
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Pre-clinical program for trypanosomiasis vaccine 
underway - if successful, could provide a solution 
for an important agricultural and development 
issue
Fraunhofer’s transient, plant-based expression 
system could have utility for inexpensive 
production of highly immunogenic recombinant 
vaccines for developing world
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Partners
Dr. Vidadi Yusibov, Director of the 
Fraunhofer Center for Molecular 
Biotechnology, USA
Dr. Roger Pritchard, Professor, McGill 
University, Canada
Dr. George Lubega, Professor, Makerere
University, Uganda
